- Home
- AIRJW vs MRK Comparison
AIRJW vs MRK Comparison
Compare AIRJW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRJW
- MRK
- Stock Information
- Founded
- AIRJW N/A
- MRK 2000
- Country
- AIRJW United States
- MRK United States
- Employees
- AIRJW 17
- MRK N/A
- Industry
- AIRJW Blank Checks
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- AIRJW Finance
- MRK Health Care
- Exchange
- AIRJW Nasdaq
- MRK Nasdaq
- Market Cap
- AIRJW N/A
- MRK 218.8B
- IPO Year
- AIRJW N/A
- MRK N/A
- Fundamental
- Price
- AIRJW $1.24
- MRK $88.04
- Analyst Decision
- AIRJW
- MRK Buy
- Analyst Count
- AIRJW 0
- MRK 15
- Target Price
- AIRJW N/A
- MRK $105.14
- AVG Volume (30 Days)
- AIRJW 19.1K
- MRK 12.1M
- Earning Date
- AIRJW 03-21-2025
- MRK 10-30-2025
- Dividend Yield
- AIRJW N/A
- MRK 3.70%
- EPS Growth
- AIRJW N/A
- MRK 20.41
- EPS
- AIRJW 4.07
- MRK 6.49
- Revenue
- AIRJW N/A
- MRK $63,616,000,000.00
- Revenue This Year
- AIRJW N/A
- MRK $1.76
- Revenue Next Year
- AIRJW N/A
- MRK $5.11
- P/E Ratio
- AIRJW $2.05
- MRK $13.49
- Revenue Growth
- AIRJW N/A
- MRK 1.82
- 52 Week Low
- AIRJW $1.11
- MRK $73.31
- 52 Week High
- AIRJW $1.32
- MRK $106.62
- Technical
- Relative Strength Index (RSI)
- AIRJW 53.27
- MRK 60.20
- Support Level
- AIRJW $1.17
- MRK $86.91
- Resistance Level
- AIRJW $1.50
- MRK $88.79
- Average True Range (ATR)
- AIRJW 0.22
- MRK 1.45
- MACD
- AIRJW -0.01
- MRK 0.14
- Stochastic Oscillator
- AIRJW 29.32
- MRK 86.67
About AIRJW Montana Technologies Corporation Warrant
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).